Latest news with #RSU
Hans India
a day ago
- Entertainment
- Hans India
‘Veede Mana Vaarasudu' set for release on July 18
Veede Mana Vaarasudu, a socially relevant and emotionally charged drama rooted in the struggles of farmers, is all set to hit theatres across the Telugu states on July 18. Written, directed, produced, and headlined by Ramesh Uppu (RSU), the film promises a heartfelt cinematic experience with strong social messaging. In addition to playing the lead role, RSU has taken on multiple creative responsibilities—writing the screenplay, penning dialogues and lyrics, and even lending his voice to the film's songs. The film is produced under the R.S. Arts banner and is presented by U Ramadevi. Starring Lavanya Reddy and Sarvani Mohan alongside RSU, the film also features supporting performances by Sammetha Gandhi, Vijay Rangaraju, Anand Bharathi, Guduru Kishore, and Shilpa (Vizag). The film recently completed its censor formalities and received positive feedback from board members, who appreciated its depiction of family values, the challenges faced by farmers, and its hard-hitting commentary on youth drug abuse. Speaking about the film, RSU shared, 'Veede Mana Vaarasudu carries a message that society needs today. The emotional layers in the story are sure to strike a chord with viewers. Encouragement from the censor board and early viewers has reaffirmed our faith in the film. We hope the audience supports this honest effort and joins us in theatres.' Promotional activities have already begun, generating strong interest. A pre-release event is planned for June 29, while early premiere shows for select dignitaries have garnered praise, further adding to the film's buzz. With its powerful narrative and socially conscious themes, Veede Mana Vaarasudu aims to touch hearts and spark conversations.
Business Wire
12-06-2025
- Business
- Business Wire
NEUPATH HEALTH ANNOUNCES VOTING RESULTS FROM THE ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS
TORONTO--(BUSINESS WIRE)--NeuPath Health Inc. (TSXV:NPTH), ('NeuPath' or the 'Company'), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced the voting results from its Annual General and Special Meeting of Shareholders (the 'Meeting') held on June 11, 2025 and the grant of stock options ('Options') and restricted share units ('RSUs'). All figures are in Canadian dollars, unless otherwise noted. The results of the director elections were as follows: The shareholders of the Company also voted: (i) to reappoint Ernst & Young LLP, Chartered Professional Accountants, Licensed Public Accountants, as auditors of the Company for the ensuing year, (ii) to approve the Company's amended and restated stock option plan in the form attached as Schedule 'A' to the management information circular dated April 22, 2025 prepared in connection with the Meeting (the 'Stock Option Plan'), and (iii) to approve the Company's amended and restated restricted share unit plan in the form attached as Schedule 'B' to the management information circular dated April 22, 2025 prepared in connection with the Meeting (the 'RSU Plan'). Amendments to the RSU Plan At the Meeting, the Company proposed the adoption of the RSU Plan which was amended to increase the maximum number of common shares of the Company ('Common Shares') issuable thereunder from 3,000,000 Common Shares to 5,000,000 Common Shares. At the Meeting, 99.38% shareholder votes cast were in favour of adopting the RSU Plan. Issuance of Stock Options and Restricted Share Units On June 12, 2025, NeuPath granted an aggregate of 150,000 Options to non-executive directors of the Company at an exercise price of $0.26 per share, with an expiry date of June 12, 2032. The Options are subject to time-based vesting and will fully vest on June 12, 2026. The terms of the Options granted are in accordance with the Stock Option Plan. In addition, on June 12, 2025, the Company granted an aggregate of 60,000 RSUs to the same non-executive directors of the Company. The RSUs are subject to time-based vesting in accordance with the policies of the TSX Venture Exchange. RSUs granted will fully vest on June 12, 2026. The terms of the RSUs granted are in accordance with the RSU Plan. About NeuPath NeuPath operates a network of healthcare clinics and related businesses focused on improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centered multidisciplinary care. We operate a network of medical clinics in Ontario and Alberta that provide comprehensive assessments and rehabilitation services to patients with chronic pain, musculoskeletal/back injuries, sports related injuries and concussions. In addition, NeuPath provides workplace health services and independent medical assessments to employers and disability insurers through a national network of healthcare providers, as well as contract research services to pharmaceutical and biotechnology companies. NeuPath is focused on enabling each individual to live their best life. For additional information, please visit
Yahoo
12-06-2025
- Business
- Yahoo
NEUPATH HEALTH ANNOUNCES VOTING RESULTS FROM THE ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS
TORONTO, June 12, 2025--(BUSINESS WIRE)--NeuPath Health Inc. (TSXV:NPTH), ("NeuPath" or the "Company"), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting") held on June 11, 2025 and the grant of stock options ("Options") and restricted share units ("RSUs"). All figures are in Canadian dollars, unless otherwise noted. The results of the director elections were as follows: Name Votes in Favour % Votes in Favour Votes Withheld % Votes Withheld Jolyon Burton 15,780,716 99.99% 1,000 0.01% Daniel Chicoine 15,780,716 99.99% 1,000 0.01% Sasha Cucuz 15,775,716 99.96% 6,000 0.04% Dan Legault 15,780,716 99.99% 1,000 0.01% Joseph Walewicz 15,780,716 99.99% 1,000 0.01% The shareholders of the Company also voted: (i) to reappoint Ernst & Young LLP, Chartered Professional Accountants, Licensed Public Accountants, as auditors of the Company for the ensuing year, (ii) to approve the Company's amended and restated stock option plan in the form attached as Schedule "A" to the management information circular dated April 22, 2025 prepared in connection with the Meeting (the "Stock Option Plan"), and (iii) to approve the Company's amended and restated restricted share unit plan in the form attached as Schedule "B" to the management information circular dated April 22, 2025 prepared in connection with the Meeting (the "RSU Plan"). Amendments to the RSU Plan At the Meeting, the Company proposed the adoption of the RSU Plan which was amended to increase the maximum number of common shares of the Company ("Common Shares") issuable thereunder from 3,000,000 Common Shares to 5,000,000 Common Shares. At the Meeting, 99.38% shareholder votes cast were in favour of adopting the RSU Plan. Issuance of Stock Options and Restricted Share Units On June 12, 2025, NeuPath granted an aggregate of 150,000 Options to non-executive directors of the Company at an exercise price of $0.26 per share, with an expiry date of June 12, 2032. The Options are subject to time-based vesting and will fully vest on June 12, 2026. The terms of the Options granted are in accordance with the Stock Option Plan. In addition, on June 12, 2025, the Company granted an aggregate of 60,000 RSUs to the same non-executive directors of the Company. The RSUs are subject to time-based vesting in accordance with the policies of the TSX Venture Exchange. RSUs granted will fully vest on June 12, 2026. The terms of the RSUs granted are in accordance with the RSU Plan. About NeuPath NeuPath operates a network of healthcare clinics and related businesses focused on improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centered multidisciplinary care. We operate a network of medical clinics in Ontario and Alberta that provide comprehensive assessments and rehabilitation services to patients with chronic pain, musculoskeletal/back injuries, sports related injuries and concussions. In addition, NeuPath provides workplace health services and independent medical assessments to employers and disability insurers through a national network of healthcare providers, as well as contract research services to pharmaceutical and biotechnology companies. NeuPath is focused on enabling each individual to live their best life. For additional information, please visit NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS THE RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. View source version on Contacts For more information, please contact: Jeff ZygourasChief Financial Officerinfo@ (905) 858-1368 Sign in to access your portfolio
Globe and Mail
10-06-2025
- Business
- Globe and Mail
Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on June 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 74,000 shares of its common stock and granted an aggregate of 48,850 restricted stock unit ('RSU') awards to 20 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the '2021 Inducement Plan'). The stock options and RSUs were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4). The 2021 Inducement Plan is used exclusively for granting equity awards to individuals who were not previously employees of Crinetics, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with Crinetics, pursuant to Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $33.08 per share, which is equal to the closing price of Crinetics' common stock on the Nasdaq Global Select Market on June 10, 2025. The shares subject to the stock options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter, subject to each employee's continued employment with Crinetics on such vesting dates. The RSUs will vest over four years in equal annual installments beginning on the one-year anniversary of the applicable vesting commencement date, also subject to each employee's continued employment with Crinetics on such vesting dates. The stock option and RSU awards are subject to the terms and conditions of the 2021 Inducement Plan and the terms and conditions of an applicable stock option award agreement or RSU award agreement covering the respective grant. About Crinetics Pharmaceuticals Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics' lead development candidate, paltusotine, is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome. All of the company's drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications. Investors: Gayathri Diwakar Head of Investor Relations gdiwakar@ (858) 345-6340
Indian Express
25-05-2025
- Politics
- Indian Express
What was the Radical Students Union, which gave rise to many Maoist leaders in India?
In April 1972, a young student leader of Osmania University (OU) in Hyderabad, George Reddy, was allegedly killed by members of a right-wing group. While this led to widespread protests and student mobilisation at the time, almost three years later, on February 20, 1975, a students' outfit — Radical Students Union (RSU) — was born out of the embers of this incident. The outfit was banned by the government of India in 1992. While the RSU as an outfit gradually lost steam, 50 years after its formation, its influence is still alive, as two of the top Maoists in the country – the slain Nambala Keshava Rao alias Basavaraju and the next in command Thippiri Tirupathi alias Devuji – are both products of RSU. So is the spokesperson and the current ideological fountainhead of the Maoist party, Mallojula Venugopal Rao alias Sonu. As the Communist Party of India (Maoist) seems to be nearing their endgame, with the Centre setting a deadline of March 31, 2026 to mark the end of Naxalism in India, The Indian Express takes a look at the banned students' outfit that contributed the rank and file of the party. Early days 'The RSU was a prominent student organisation born out of several incidents, including the Naxalbari movement of the 1960s and '70s which led to widespread students' uprising in the country. George Reddy's killing was a trigger,' said a former students union leader on the condition of anonymity. An intelligence official from Telangana who has mapped the origins and growth of the RSU said, 'At the time, campuses were up in flames, including Osmania University and REC (Regional Engineering College, which later turned into National Institute of Technology) Warangal. From these students' movements, several people were recruited into the underground party.' At the time, RSU was considered the student union of People's War Group (or the Communist Party of India (Marxist–Leninist) People's War). 'There was a student outfit that represented PWG, the Progressive Democratic Students Union (PDSU). But the PDSU split in 1975 to form the RSU, which was more radical in its outlook,' the official said. These students considered academics only a tool for social revolution, a student leader said. 'Across campuses, students used to talk about issues gripping the country, such as poverty and casteism. In those days, the students led protests in villages against feudal landlords,' said the former student leader. For example, students were part of the Srikakulam Peasant uprising in the undivided Andhra Pradesh that lasted between 1967 and 1970. 'The RSU basically referenced several social movements and built its cadre. The cadre later went underground,' an internal security official told the Indian Express. There were times when the reach of the RSU was such that their underground and overground cadre roamed freely in the villages of Warangal and Karimnagar, a state official explained. These were called the 'Go to the Villages' campaigns. 'The RSU even contested elections in some campuses, including REC-Warangal. Most of the top leadership of the Maoist party — many of whom are from the Telugu-speaking states — have some link to the RSU,' the official said. Ban, and decline In Hyderabad, a 50-year remembrance event of the RSU was held on February 20. One of the organisers of the event, N Venugopal, later wrote, 'There was not a single student issue left unaddressed by the RSU. The RSU's commitment to bringing social awareness to students and the people and involving them in struggles for their community's rights, along with building relationships with the masses, was crucial.' After the party was banned, its members remained involved with other Maoist groups. A top internal security official said, 'RSU's influence waned because of the ban. But the cadre was always active in some or the other frontal organisation of the Maoists.' In 2004, when the People's War and Maoist Communist Centre merged to form the CPI (Maoist), the RSU was fully subsumed underground. 'Offshoots came only in the form of some writers' collectives and such. The state managed to curb this militant outfit even before it could complete its silver jubilee,' the official said.
